CLINICAL TRIALS PROFILE FOR ROCEPHIN

All Clinical Trials for ROCEPHIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035347 ↗	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia	Completed	Pfizer	Phase 4	2001-01-01	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00037479 ↗	Brain Imaging and Retreatment Study of Persistent Lyme Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1999-12-01	The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.
NCT00538694 ↗	Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia	Completed	Cubist Pharmaceuticals LLC	Phase 3	2000-10-31	To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
NCT00540072 ↗	Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae	Completed	Cubist Pharmaceuticals LLC	Phase 3	2001-07-30	A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Stanley Medical Research Institute	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Yale University	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00838864 ↗	Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding	Completed	Far Eastern Memorial Hospital	Phase 4	2009-03-01	Prophylactic antibiotics have been routinely recommended for cirrhotic patients with upper gastrointestinal bleeding recently. However, the regimen and duration of its use remain an inconclusive issue. Quinolones and 3rd generation cephalosporins have been more often used for prophyalxis recently. The duration for antibiotic usage were variable in the literatures, ranged from 4-10 days. The latest guideline from AASLD in 2007 was 7 days. In the survey of infections in cirrhotic patients with UGI bleeding performed by Bernard et al, most infections occurred in the first 5 days and half within the first 48 hours. Therefore, considering the cost-effectiveness and drug resistance issues, the necessity for such prophylaxis for 7 days may need to be re-evaluated. The purpose of our study is to investigate the antibiotic prophylaxis duration for cirrhotic patients with acute gastro-esophageal variceal bleeding. We will enroll those patients suffering from variceal bleeding documented by endoscopic examination and without apparent evidence of infection. Those who have received antibiotics within 2 weeks, are less than 18 years old, get pregnant, have malignancy other than HCC, have allergy to ceftrioxone are excluded. After receiving well explanation and giving consent, these patients are randomly allocated to 2 groups and receive prophylactic antibiotic just after endoscopic examination; Group I: receiving ceftriaxone 500 mg iv bolus stat and then q12h for 3 days, Group II: receiving ceftriaxone 500 mg iv bolus stat and then q12h for 7 days. They will receive appropriate endoscopic treatment for gastro-esophgeal varices and glypressin 1mg q6h for 3 days. They will start to feed on the 2nd day if not contraindicated. The 2nd endoscopic treatment for varices will be performed 2 weeks later. We record the demographic data, vital signs, transfusion amount; check hemogram, U/A, CXR, ascites routine (with apparent ascites), classification of variceal size and Child-Pugh classification. We monitor the events of rebleeding & infection, transfusion amount and hospitalization days We use rebleeding rate within 14 days as the primary end point. It is defined as the following events after initial stabilization of vital signs for 24 hours; (1): recurrence of hematemesis or bloody stool (2); need of transfusion more than 2 unit of blood and systolic pressure < 100 mmHg or pulse rate > 100/mn. We use infection rate during admission and mortality rate within 28 days as secondary end points.

Clinical Trial Conditions for ROCEPHIN

Condition Name

Condition Name for ROCEPHIN
Intervention	Trials
Pneumonia, Bacterial	2
Coagulase Negative Staphylococcal Infection	1
Lyme Disease	1
Staphylococcal Infections	1

Condition MeSH

Condition MeSH for ROCEPHIN
Intervention	Trials
Infection	3
Pneumonia	3
Infections	3
Pneumonia, Bacterial	2

Clinical Trial Locations for ROCEPHIN

Trials by Country

Trials by Country for ROCEPHIN
Location	Trials
United States	21
Japan	15
Canada	6
Taiwan	3
France	2

Trials by US State

Trials by US State for ROCEPHIN
Location	Trials
Pennsylvania	2
Ohio	2
New York	2
Michigan	2
California	2

Clinical Trial Progress for ROCEPHIN

Clinical Trial Phase

Clinical Trial Phase for ROCEPHIN
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	4
Phase 2	6

Clinical Trial Status

Clinical Trial Status for ROCEPHIN
Clinical Trial Phase	Trials
Completed	9
Unknown status	4
Recruiting	3

Clinical Trial Sponsors for ROCEPHIN

Sponsor Name

Sponsor Name for ROCEPHIN
Sponsor	Trials
Pfizer	3
Cubist Pharmaceuticals LLC	2
Far Eastern Memorial Hospital	1

Sponsor Type

Sponsor Type for ROCEPHIN
Sponsor	Trials
Other	35
Industry	7
NIH	2

Last updated: July 26, 2026

Rocephin (ceftriaxone) Clinical Trials Update, Market Analysis, and Revenue Projection (2026-2035)

Executive summary

• Drug: ROCEPHIN (ceftriaxone).
• Clinical trials: New late-stage value-creation trials are limited versus broader competitive activity, with most incremental evidence focused on pediatric dosing/PK, formulation-use expansions, and comparative/real-world endpoints rather than new phase-3 efficacy programs.
• Market: ROCEPHIN remains a high-volume hospital antibiotic with stable demand driven by community-acquired infections, sepsis pathways, meningitis, and intra-abdominal infections.
• Pricing and reimbursement: U.S. and EU markets are exposed to generic-led pricing pressure, with demand growth more dependent on hospital formularies and guideline positioning than on price increases.
• Projection (base case): Global ceftriaxone class revenue is expected to grow at low single digits through 2030, with ROCEPHIN declining in share in markets with entrenched generics.
• Key risks: Pediatric stewardship constraints, antimicrobial resistance dynamics, and hospital antibiotic substitution to alternative beta-lactams and parenteral cephalosporin options.

No actionable, drug-specific clinical-trial dataset, ROCEPHIN revenue by geography, or FDA/EMA exclusivity status can be produced from the information available in this chat without external source ingestion.

What clinical trials are currently active for Rocephin (ceftriaxone)?

Featured snippet answer: Active ceftriaxone trials tend to cluster around pediatric pharmacokinetics, dose optimization, comparative effectiveness, and safety/PK in special populations, with fewer novel phase-3 programs relative to branded “new molecular entity” patterns.

Trial types that typically drive new ceftriaxone publications

• Pediatric dosing and PK/PD
  Focus: weight-based dosing, renal/hepatic impairment exposure, clearance changes, and exposure targets for common infection syndromes.
• Meningitis and CNS infection protocols
  Focus: comparative outcomes, duration-of-therapy investigations, and adherence to guideline dosing.
• Sepsis bundle impact studies
  Focus: time-to-antibiotic, appropriateness metrics, and culture-adjusted therapy outcomes.
• Comparative observational cohorts
  Focus: ceftriaxone versus piperacillin-tazobactam, cefepime, and carbapenem-sparing strategies.
• Local guideline alignment
  Focus: antimicrobial stewardship and pathway-based utilization patterns.

How to interpret “trial activity” for ROCEPHIN specifically

ROCEPHIN is a formulary antibiotic brand of a widely available active ingredient. Clinical trial visibility often reflects:

• independent investigator-led work on ceftriaxone rather than brand-sponsored programs
• manufacturing or administration refinements (e.g., compatibility, reconstitution handling, infusion timing)
• regional regulatory workups rather than global phase-3 efficacy replication

How does Rocephin’s clinical evidence compare with other injectable cephalosporins?

Featured snippet answer: Ceftriaxone’s clinical profile is generally strong on broad gram-negative coverage and convenient dosing, which supports its role in hospital pathways even as newer agents and combination regimens compete.

Comparative positioning in hospitals

• Versus cefotaxime: frequent substitution depending on local susceptibility patterns and availability.
• Versus ceftazidime/cefepime: often used when pseudomonal risk is higher; ceftriaxone remains common when resistance patterns support it.
• Versus piperacillin-tazobactam: used in mixed infections depending on stewardship pathways and renal toxicity profiles.
• Versus carbapenems: stewardship programs push carbapenem-sparing where ceftriaxone sensitivity supports it.

Competitive implication for ROCEPHIN

Even with stable clinical evidence, brand economics are pressured by:

• generic supply
• tender-based contracting
• therapeutic interchange rules in many systems

What is the current market size for Rocephin (ceftriaxone) and how is it trending?

Featured snippet answer: ROCEPHIN demand tracks hospital antibiotic utilization. Market growth is typically modest because ceftriaxone is long-established and faces sustained generic substitution.

Demand drivers that keep utilization steady

• Sepsis and empiric therapy protocols (where ceftriaxone is recommended or used as a default option)
• Pediatric indications and guideline inclusion (where appropriate)
• Meningitis protocols and other localized infection bundles
• Seasonal shifts in respiratory and GI infection admissions

Headwinds

• Price compression from generic penetration
• Guideline revisions that favor broader-spectrum agents for certain syndromes
• Resistance trends affecting selection and duration decisions

Which regions generate the most sales for Rocephin and what is the share outlook vs generics?

Featured snippet answer: Market structure varies by region, but in most mature markets ROCEPHIN’s share declines relative to generic ceftriaxone, with higher persistence where branding is protected by contracting preferences or supply constraints.

Region-level dynamics (directional)

• U.S.: heavily generic; ROCEPHIN maintains presence mainly through contracting and pharmacy supply practices.
• EU/UK: similarly generic-intensive; brand share typically declines while overall ceftriaxone utilization remains significant.
• Emerging markets: higher growth potential in absolute volumes, with competitive pressure from local generics.

What are the exclusivity and patent-expiration timelines for Rocephin (ceftriaxone) in the U.S. and EU?

Featured snippet answer: ROCEPHIN is a legacy product of an established API (ceftriaxone), so brand-level exclusivity is largely expired. Current competitive constraints are driven by formulation/labeling/manufacturing patents where they exist and by regulatory exclusivity if any secondary exclusivity applies.

Practical effects on market access

• Generic entry is generally not meaningfully blocked by primary ceftriaxone patents.
• Remaining differentiation is usually non-API: packaging, manufacturing process details, and certain labeling constructs.

How many patents cover Rocephin (ceftriaxone) and what is the strength of the patent estate?

Featured snippet answer: The patent estate for ceftriaxone is not expected to create broad, enforceable long-term exclusivity for the core active ingredient in major jurisdictions; remaining enforceable rights, where present, are likely narrow and secondary.

Where patent strength usually shows up for legacy injectables

• manufacturing process patents
• stability and formulation parameters
• device/administration-related claims (less common for classic vials/solutions)
• specific medical use claims (if any)

What generic entry risks exist for Rocephin and how fast could share erode?

Featured snippet answer: Generic entry risk is persistent in pricing and tender settings. Share erosion is typically governed by contracting cycles and hospital formulary switching, not by discrete patent events.

Common drivers of rapid substitution

• tender award to lowest-cost supplier
• automatic therapeutic interchange
• inventory and procurement harmonization
• shortages or supply allocation that temporarily distort share

Which companies compete with Rocephin in ceftriaxone injectable markets?

Featured snippet answer: Competition is dominated by generic manufacturers and wholesalers. Exact vendor lists depend on country and purchasing segment.

Competitive landscape structure

• Global generics: multiple suppliers for powder-in-vial or ready-to-use presentations
• Hospital distribution: brand and generic availability depends on local distribution agreements
• Tender pricing: often determines near-term utilization share

What is the FDA regulatory status of Rocephin (ceftriaxone) and does it affect market access?

Featured snippet answer: ROCEPHIN is an FDA-approved prescription injectable. Market access for most competitors depends on FDA approval pathways for generics of ceftriaxone and current labeling coverage.

Key regulatory signals that matter commercially

• label-driven indications and dosing language
• approved presentations and strengths
• manufacturing site approvals and inspection outcomes

How does Rocephin’s formulation and dosing affect comparative use in hospitals?

Featured snippet answer: Dosing convenience, administration constraints, and compatibility affect hospital choice among injectable cephalosporins as much as efficacy in standardized pathways.

Formulation and administration factors

• reconstitution handling and dilution flexibility
• infusion compatibility with common IV fluids
• storage conditions and stability
• administration timing constraints for specific inpatient workflows

What market forecast should investors and marketers use for Rocephin through 2035?

Featured snippet answer: A base-case forecast should model low single-digit class growth with brand share erosion and revenue normalization at lower net pricing.

Base-case revenue framework (directional, model-ready)

Because no verified ROCEPHIN revenue-by-year dataset is available in this chat, the forecast framework should be built using:

• global hospital injectable antibiotic market growth assumptions
• ceftriaxone class volume trends
• brand net price vs generic blended price differentials
• tender-driven share shifts and supply continuity

Scenario approach (inputs for a model)

• Conservative: volume flat to slight decline in mature markets; price declines continue; modest growth in emerging markets.
• Base case: stable global volume growth driven by hospital admissions and standardized sepsis pathways; share drift to generics continues.
• Upside: stewardship-resistant selection increases ceftriaxone usage where susceptibility supports it; fewer supply disruptions.
• Downside: resistance and guideline changes reduce ceftriaxone empiric use; increased substitution to broader cephalosporins and beta-lactam/beta-lactamase inhibitors.

Outputs to compute in your revenue model

• Units (grams/vials) by region
• Net sales by region = units × net price
• Share = ROCEPHIN units / total ceftriaxone units
• Sensitivity: % price differential and share erosion per tender cycle

What patent litigation, settlements, or Paragraph IV challenges affect Rocephin?

Featured snippet answer: For legacy ceftriaxone brands, litigation typically involves generic entry and Orange Book-listed secondary patents, but a specific, up-to-date litigation docket cannot be produced from information present in this chat.

Litigation impact on market access

• settlement agreements can delay generic launches by months to years
• injunction risk is usually narrow and tied to specific listed patents

Key Takeaways

• ROCEPHIN is a legacy, high-volume hospital antibiotic where clinical evidence supports utilization, but brand economics are constrained by generic competition.
• Current “clinical trial updates” for ceftriaxone are more likely to be pediatric PK, dosing optimization, and comparative/real-world evidence than brand-changing late-stage trials.
• Market outlook is best modeled as low growth ceftriaxone class demand with declining ROCEPHIN share in mature markets due to contracting and tender pricing.
• Patent and exclusivity effects are unlikely to be the primary driver of near-to-mid-term commercial outcomes; procurement dynamics and resistance/guideline selection are.

FAQs

1. Does ceftriaxone still get new FDA labeling updates that affect ROCEPHIN use in hospitals?
2. How do antimicrobial stewardship programs change ceftriaxone empiric selection for sepsis?
3. What are the main pediatric dosing considerations for ceftriaxone that show up in recent studies?
4. Which drug classes most often substitute for ceftriaxone in inpatient treatment pathways?
5. How do hospital tender cycles typically shift injectable antibiotic share between branded and generic suppliers?

References

1. (No citable sources were provided or accessible within this chat context.)